Clinical Trials Logo

Cerebral Infarction clinical trials

View clinical trials related to Cerebral Infarction.

Filter by:

NCT ID: NCT06120725 Completed - Ischemic Stroke Clinical Trials

Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke

Start date: September 1, 2021
Phase: Phase 3
Study type: Interventional

Along with the current clinical trial, the efficacy and safety of 180 mg loading dose of ticagrelor administered within 24 hours of first-ever large-vessel ischemic stroke compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.

NCT ID: NCT06120218 Recruiting - Acute Stroke Clinical Trials

Tandem Occlusion After Emergent Stenting in Acute Ischemic Stroke

TOESIS
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

In acute ischemic stroke due to tandem occlusion, the emergent stenting has recently become an endovascular treatment option combining with mechanical thrombectomy to achieve recanalization. However, the data on the beneficial endovascular management of tandem occlusion in two circulations is still limited. The purpose of our study was to compare the improvement of clinical outcome between two circulations after emergent stenting at 3 months.

NCT ID: NCT06100718 Recruiting - Ischemic Stroke Clinical Trials

Discovery of New Cancer in the 1-year Follow-up After Ischemic Stroke in Patients at Risk: The INVISIBLE-1 Study

INVISIBLE-1
Start date: January 1, 2022
Phase:
Study type: Observational

INVISIBLE-1 aims to prospectively follow patients up to one year after ischemic stroke to: 1. Determine the cumulative incidence of occult cancer in patients with embolic stroke of undetermined source (ESUS) and elevated D-dimer 2. Describe occult cancer characteristics and spontaneous course of occult cancer Methodology The investigators will include 370 stroke patients with elevated D-dimer (≥ 820 μg/L) at the time of stroke, suspicion of ESUS after initial workup and without known cancer. The investigators will perform a follow-up telephone interview at one year to assess the occurrence of a new cancer and characterize the course of the disease. Significance Determining the real incidence of occult cancer in high-risk patients will help support the implementation of screening trials in the future. Faster detection and treatment of occult cancers would significantly impact patient' outcomes by offering faster cancer treatment and optimal secondary stroke prevention.

NCT ID: NCT06085378 Not yet recruiting - Type 2 Diabetes Clinical Trials

Efficacy and Safety of Urinary Kallidinogenase in the Treatment of Acute Ischemic Stroke Combined With Type 2 Diabetes Mellitus

TK-SEEK
Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This study is a multicenter, randomized, double-blind, placebo parallel control study, aim to evaluate the efficacy and safety of human urinary kallidinogenase in the treatment of acute ischemic stroke with type 2 diabetes.

NCT ID: NCT06078995 Recruiting - Ischemic Stroke Clinical Trials

Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China

TTT-AIS CHINA
Start date: April 2, 2023
Phase:
Study type: Observational

The objective of the study is to investigate the effectiveness and safety of rhTNK-tPA in acute ischemic stroke patients within 4.5 hours of symptom onset in a real-world clinical setting.

NCT ID: NCT06078215 Recruiting - Clinical trials for Acute Ischemic Stroke

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

CERBERUS
Start date: January 10, 2023
Phase: Phase 4
Study type: Interventional

The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against hemorrhagic transformation in ischemic stroke patients after reperfusion therapy (i.e. thrombolysis and/or mechanical thrombectomy).

NCT ID: NCT06077305 Not yet recruiting - Ischemic Stroke Clinical Trials

A Registry Study of Microcirculation Disorder After Cerebral Small Vessel Disease and Ischemic Stroke

MODEST
Start date: October 30, 2023
Phase:
Study type: Observational

This study aims to construct a registry platform for microcirculatory disorders in a large sample of Chinese patients with cerebral small vessel disease and ischemic stroke; To explore the role of microcirculatory disorders in different types of cerebral small vessel disease and iachemic stroke, as well as their pathogenesis, severity, and prognosis; And to research on the drug treatment of microcirculatory disorders for cerebral small vessel disease and stroke in the real world.

NCT ID: NCT06069973 Not yet recruiting - Ischemic Stroke Clinical Trials

Using Machine Learning and Biomarkers for Early Detection of Delayed Cerebral Ischemia

CIDAIBASSAH
Start date: September 1, 2024
Phase:
Study type: Observational

The overall goal of this project is to determine if machine learning and analysis of neurospecific biomarkers can enable early detection of upcoming or ongoing cerebral ischaemia in patients suffering from subarachnoid haemorrhage with altered consciousness due to cerebral injury or sedation. Analyses of heart rate variability, electroencephalgraphy,nearinfrared spectroscopy, cerebral autoregulation, and brain injury specific biomarkers in blood and cerebrospinal fluid will be performed.

NCT ID: NCT06052969 Recruiting - Clinical trials for Cerebral Arterial Disease

Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

PERFUSION AIS
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

Prospective, multi-center, single-arm early feasibility study enrolling a minimum of 15 subjects at up to a minimum of 3 active investigational sites in the United States. The subjects must be diagnosed with acute ischemic stroke (AIS), must be post-mechanical thrombectomy, will have had intravenous thrombolytics, and have a visible MCA, ACA or PCA occlusive clot on initial angiographic imaging. Each subject will receive the Pulse NanoMED procedure after attempted neurovascular therapy to achieve better reperfusion.

NCT ID: NCT06045156 Recruiting - Clinical trials for Acute Ischemic Stroke

Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke

Start date: April 10, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT